Cover Image

Ikaria Inc.的產品平台分析

Ikaria Inc. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 283210
出版日期 內容資訊 英文 23 Pages
Back to Top
Ikaria Inc.的產品平台分析 Ikaria Inc. - Product Pipeline Review - 2014
出版日期: 2014年11月24日 內容資訊: 英文 23 Pages



Ikaria Inc.是總公司設置於美國,參與需要重病照護患者的生物學性治療解決方案及介入之開發與流通的公司。提供急性重大疾病或傷害造成的生命垂危患者之照護。該公司之事業有醫藥品製造、臨床研究、給藥系統開發、事業開發、專利、研究開發、銷售及行銷、流通,此外更提供加護病房的重病照護服務。

本報告提供Ikaria Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,加上最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。


Ikaria Inc.的基本資料

  • Ikaria Inc.概要
  • 主要資訊
  • 企業資料

Ikaria Inc.:R&D概要

  • 主要的治療範圍

Ikaria Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Ikaria Inc.:開發中產品概況

  • 後期階段產品開發中產品
    • 第三階段的產品/聯合治療模式

Ikaria Inc.:藥物簡介

  • IK-3001
  • Inomax
  • terlipressin

Ikaria Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Ikaria Inc.:最新的開發平台情形

Ikaria Inc.:開發暫停中的計劃

Ikaria Inc.:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司



Product Code: GMDHC06545CDB


Global Markets Direct's, 'Ikaria Inc. - Product Pipeline Review - 2014', provides an overview of the Ikaria Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ikaria Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • The report provides brief overview of Ikaria Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Ikaria Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Ikaria Inc.'s pipeline products

Reasons to buy

  • Evaluate Ikaria Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Ikaria Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Ikaria Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Ikaria Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ikaria Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Ikaria Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Ikaria Inc. Snapshot
    • Ikaria Inc. Overview
    • Key Information
    • Key Facts
  • Ikaria Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Ikaria Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Ikaria Inc. - Pipeline Products Glance
    • Ikaria Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
  • Ikaria Inc. - Drug Profiles
    • IK-3001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Inomax
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • terlipressin
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Ikaria Inc. - Pipeline Analysis
    • Ikaria Inc. - Pipeline Products by Target
    • Ikaria Inc. - Pipeline Products by Route of Administration
    • Ikaria Inc. - Pipeline Products by Molecule Type
    • Ikaria Inc. - Pipeline Products by Mechanism of Action
  • Ikaria Inc. - Recent Pipeline Updates
  • Ikaria Inc. - Dormant Projects
  • Ikaria Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Ikaria Inc., Key Information
  • Ikaria Inc., Key Facts
  • Ikaria Inc. - Pipeline by Indication, 2014
  • Ikaria Inc. - Pipeline by Stage of Development, 2014
  • Ikaria Inc. - Monotherapy Products in Pipeline, 2014
  • Ikaria Inc. - Phase III, 2014
  • Ikaria Inc. - Pipeline by Target, 2014
  • Ikaria Inc. - Pipeline by Route of Administration, 2014
  • Ikaria Inc. - Pipeline by Molecule Type, 2014
  • Ikaria Inc. - Pipeline Products by Mechanism of Action, 2014
  • Ikaria Inc. - Recent Pipeline Updates, 2014
  • Ikaria Inc. - Dormant Developmental Projects,2014
  • Ikaria Inc., Subsidiaries

List of Figures

  • Ikaria Inc. - Pipeline by Top 10 Indication, 2014
  • Ikaria Inc. - Pipeline by Top 10 Target, 2014
  • Ikaria Inc. - Pipeline by Top 10 Route of Administration, 2014
  • Ikaria Inc. - Pipeline by Top 10 Molecule Type, 2014
  • Ikaria Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top